Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MP0317 |
Synonyms | |
Therapy Description |
MP0317 consists of a CD40 agonist cross-linked to fibroblast activation protein (FAP), which may activates anti-tumor immunity within tumor microenvironment (Cancer Res 2020;80(16 Suppl):Abstract nr 1073). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MP0317 | MP-0317|MP 0317 | MP0317 consists of a CD40 agonist cross-linked to fibroblast activation protein (FAP), which may activates anti-tumor immunity within tumor microenvironment (Cancer Res 2020;80(16 Suppl):Abstract nr 1073). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Terminated | NLD | FRA | 0 |